ANXA5 and cancer: This was evidenced by the decreased viability of EAPC-treated cancer cells as measured by MTS-based assay, increased expression of apoptotic markers (e.g., cleaved forms of PARP, caspase-3), and the number of apoptotic (e.g., Annexin V-positive) cells.